---
schema_version: "secwatch.filing_event.v1"
accession: "0001601830-26-000038"
form_type: "8-K"
ticker: "RXRX"
cik: "0001601830"
company_name: "RECURSION PHARMACEUTICALS, INC."
filed_at: "2026-02-25T23:59:59+00:00"
generated_at: "2026-05-16T00:18:53.798793+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Recursion Q4 revenue $35.5M; first AI-driven clinical validation in FAP; cash runway to 2028

## Summary
- Q4 revenue $35.5M (up from $4.5M YoY); net loss $108.1M vs $178.9M; cash $753.9M.
- REC-4881 (MEK1/2) in FAP: 75% evaluable patients had reduced polyp burden at 12 weeks; 43% median reduction.
- Fifth Sanofi milestone ($4M) achieved Feb 2026; total $134M milestone payments received from Sanofi.
- 2026 cash operating expense guidance <$390M; cash runway into early 2028 without additional financing.
- REC-7735 (PI3Kα H1047R) shows >100-fold selectivity over WT; IND-enabling studies ongoing.

## SEC filing metadata
- accession: 0001601830-26-000038
- form_type: 8-K
- ticker: RXRX
- cik: 0001601830
- company_name: RECURSION PHARMACEUTICALS, INC.
- filed_at: 2026-02-25T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601830/000160183026000038/0001601830-26-000038-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601830/000160183026000038/rxrx-20260225.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601830-26-000038
- JSON: https://secwatch.observer/filing/0001601830-26-000038.json
- Plain text: https://secwatch.observer/filing/0001601830-26-000038.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.